Atorvastatin Effect on Reduction of COPD Exacerbations
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
It is a randomized, multicenter, prospective, double-blind, placebo controlled,
interventional clinical trial that will be conducted in Poland, in about 12 Hospital
Pulmonary Departments to evaluate the effectiveness of atorvastatin on the reduction of
inflammation process in patients with chronic obstructive pulmonary diseases, and possible
biomarkers for personalized treatment of COPD.